Mayo Clinic Immunotherapy Shows Promise for High‑Risk Bladder Cancer

A phase‑3 international trial led by the Mayo Clinic demonstrated that the experimental immunotherapy cretostimogene grenadenorepvec induced complete responses in 75% of patients with high‑risk bladder cancer that had recurred after standard BCG treatment, allowing most to avoid bladder removal surgery. About 60% of those responders remained cancer‑free after two years, and side effects were generally mild and limited to temporary bladder symptoms.

Experts highlight that while the rapid pace of innovation in bladder‑cancer diagnostics and therapies—such as photodynamic diagnosis, AI‑assisted pathology, and circulating tumor DNA testing—offers new clinical possibilities, the key challenge remains ensuring these advances are adopted into routine care. As Anders Neijber, chief medical officer of Photocure, notes, “innovation alone does not change care; adoption does,” emphasizing the importance of integrating promising treatments like the Mayo Clinic’s immunotherapy into standard practice to improve patient outcomes and reduce the burden on healthcare systems.